|
|
| Oncologie > Etude de marché sectorielle |
|
|
|
|
€ 170,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Février 2006 |
Taille du document : |
23 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Breast Cancer Risk
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Chinese Markets for Cancer Treatment Drugs
272 pages | Septembre 2005 |
China's demand for cancer treatmen drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's ec |
2 835,00 €
|
| |
| |
MarketWatch: Cancer
28 pages | Novembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Avril 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Drug Approvals for Cancer Indications Alphabetical Listing, 1996-2002
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Classes of Chemotherapy Drugs Used to Treat Breast Cancer
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Stakeholder Insight: Prostate Cancer - A Prostrate Market Waiting for Innovations
312 pages | Octobre 2005 |
IntroductionThe prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations.
Safety concerns with AstraZeneca's C |
12 920,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
Country Survival Rates for Breast Cancer
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the major current business issues and events, including R&D news, licensing deals, alliances and joint ventures, and regulatory decisions.
|
|
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the major current business issues and events, including R&D news, licensing deals, alliances and joint ventures, and regulatory decisions.
|
|
|
PPLSEN
|
|
|
|
|
